LONDON, July 22 /PRNewswire-FirstCall/ -- GSK announced its sales and turnover fell by less than expected in Q2. The Pharma giant also said there had been good growth in the consumer, vaccine, european and emerging markets businesses and whilst the US remains under pressure from older products going off patent, the rate of decline has slowed down.
